MNG1115
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.533
- E2F_TARGETS+0.510
- G2M_CHECKPOINT+0.453
- MYC_TARGETS_V2+0.403
- MTORC1_SIGNALING+0.356
- TNFA_SIGNALING_VIA_NFKB+0.328
- DNA_REPAIR+0.307
- UV_RESPONSE_UP+0.271
- CHOLESTEROL_HOMEOSTASIS+0.263
- MYC_TARGETS_V1+0.261
Top 10 suppressed
- UV_RESPONSE_DN-0.352
- ALLOGRAFT_REJECTION-0.303
- APICAL_SURFACE-0.278
- PROTEIN_SECRETION-0.271
- HEDGEHOG_SIGNALING-0.224
- ANDROGEN_RESPONSE-0.199
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.183
- HEME_METABOLISM-0.155
- IL2_STAT5_SIGNALING-0.122
- APICAL_JUNCTION-0.111
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG713 | — | — | 0.861 |
| 2 | MNG711 | — | — | 0.821 |
| 3 | TCGA-BB-A5HY-01A-11R-A28V-07 | — | — | 0.809 |
| 4 | BS_J483EMFP | ATRT | — | 0.807 |
| 5 | SRR8518231 | — | E | 0.799 |
| 6 | TCGA-IQ-A61G-01A-11R-A30B-07 | — | — | 0.792 |
| 7 | BSR_12_0070_A1_S79 | — | C | 0.786 |
| 8 | e255e8fa-b1c7-42bf-9934-4ea44bed860f | — | — | 0.782 |
| 9 | SRR35579811 | — | B | 0.779 |
| 10 | MNG158 | — | — | 0.771 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.533 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.453 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.403 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.356 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.328 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.307 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.271 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.263 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.261 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.257 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.209 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.202 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.189 | Idelalisib | — uncovered |
| APOPTOSIS | 0.182 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.168 | Inavolisib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.141 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.127 | Inavolisib | — uncovered |